# Abbott Laboratories (ABT) — Analyst Forecast

ABT · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/abt/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 25 | 6 | 0 | 31 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $112.00 | $123.58 | $135.00 | 12 |

Last price $101.82 (as of Oct 13, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 7, 2026 | Barclays | Initiated Coverage | Overweight | $120.00 |
| Oct 2, 2026 | Rothschild & Co | Upgraded | Neutral → Buy | $127.00 |
| Sep 8, 2026 | TD Cowen | Maintained | Buy | $135.00 |
| Aug 25, 2026 | TD Cowen | Maintained | Buy | $135.00 |
| Aug 13, 2026 | Wolfe Research | Upgraded | Peer Perform → Outperform | $130.00 |
| Jul 28, 2026 | UBS | Maintained | Buy | $125.00 |
| Jul 17, 2026 | RBC Capital | Maintained | Outperform | $130.00 |
| Jul 17, 2026 | Evercore ISI Group | Maintained | Outperform | $120.00 |
| Jul 17, 2026 | Wells Fargo | Maintained | Overweight | $112.00 |
| Jul 17, 2026 | JP Morgan | Maintained | Overweight | $120.00 |
| Jul 17, 2026 | Piper Sandler | Maintained | Overweight | $118.00 |
| Jul 17, 2026 | Citigroup | Maintained | Buy | $112.00 |
| Jul 17, 2026 | TD Cowen | Maintained | Buy | $115.00 |
| Jul 17, 2026 | BTIG | Maintained | Buy | $134.00 |
| Jul 6, 2026 | Evercore ISI Group | Maintained | Outperform | $112.00 |
| Jul 1, 2026 | Baird | Initiated Coverage | Outperform | $121.00 |
| Jun 22, 2026 | Piper Sandler | Maintained | Overweight | $115.00 |
| Apr 27, 2026 | BTIG | Maintained | Buy | $131.00 |
| Apr 20, 2026 | Barclays | Maintained | Overweight | $143.00 |
| Apr 17, 2026 | Stifel | Maintained | Buy | $120.00 |

## Frequently Asked Questions

### What is the price target for ABT stock?

The average 12-month analyst price target for Abbott Laboratories (ABT) is $123.58, with a high estimate of $135.00 and a low of $112.00, across 12 analysts.

### Is ABT a buy, sell, or hold?

Analysts covering Abbott Laboratories currently average a Buy rating: 25 buy, 6 hold and 0 sell, from 31 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for ABT?

The average price target of $123.58 implies 21.37% upside from the last price of $101.82.

### What is the latest analyst rating on ABT?

On Oct 7, 2026, Barclays initiated coverage of Abbott Laboratories at Overweight with a price target of $120.00.

## Similar Stocks

- [ISRG](https://www.lighthorse.io/tickers/isrg) — Intuitive Surgical, Inc. - Common Stock
- [MDT](https://www.lighthorse.io/tickers/mdt) — Medtronic plc. Ordinary Shares
- [DXCM](https://www.lighthorse.io/tickers/dxcm) — DexCom, Inc. - Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [TMO](https://www.lighthorse.io/tickers/tmo) — Thermo Fisher Scientific Inc Common Stock
- [BSX](https://www.lighthorse.io/tickers/bsx) — Boston Scientific Corporation Common Stock
- [ITGR](https://www.lighthorse.io/tickers/itgr) — Integer Holdings Corporation Common Stock
- [ELV](https://www.lighthorse.io/tickers/elv) — Elevance Health, Inc. Common Stock
- [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock
- [BDX](https://www.lighthorse.io/tickers/bdx) — Becton, Dickinson and Company Common Stock

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).